Preparation and characterization of a nanoparticulate formulation composed of PEG-PLA and PLA as anti-inflammatory agents

International Journal of Pharmaceutics

Volumn 385, Issue 1-2, 2010, Pages 170-175

  Ishihara, Tsutomu ^a,b   Takahashi, Miyuki ^b   Higaki, Megumu ^b   Mizushima, Yutaka ^b   Mizushima, Tohru ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

^b JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Anti inflammation; Block copolymer; Nanoparticle; PLA PLGA; Storage stability

Indexed keywords

ANTIINFLAMMATORY AGENT; BETAMETHASONE SODIUM PHOSPHATE; COPOLYMER; MACROGOL; NANOPARTICLE; POLYLACTIC ACID; POLYLACTIDE;

ADJUVANT ARTHRITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG DEGRADATION; DRUG HYDROLYSIS; DRUG IDENTIFICATION; DRUG PENETRATION; DRUG RELEASE; DRUG RETENTION; DRUG STORAGE; DRUG SYNTHESIS; FREEZE DRYING; IN VITRO STUDY; IN VIVO STUDY; INCUBATION TIME; INFLAMMATORY DISEASE; LOW TEMPERATURE; MACROPHAGE; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SURFACE PROPERTY;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ARTHRITIS, EXPERIMENTAL; BETAMETHASONE; CHEMISTRY, PHARMACEUTICAL; DELAYED-ACTION PREPARATIONS; DRUG CARRIERS; DRUG STABILITY; DRUG STORAGE; FREEZE DRYING; FREUND'S ADJUVANT; HYDROLYSIS; LACTATES; MALE; MYCOBACTERIUM; NANOPARTICLES; NANOTECHNOLOGY; PERMEABILITY; POLYETHYLENE GLYCOLS; RATS; RATS, INBRED LEW; SOLUBILITY; TECHNOLOGY, PHARMACEUTICAL; TEMPERATURE; TIME FACTORS;

EID: 72149119067     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2009.10.025     Document Type: Article

References (21)

1. Ambegia E., Ansell S., Cullis P., Heyes J., Palmer L., and MacLachlan I. Stabilized plasmid-lipid particles containing PEG-diacylglycerols exhibit extended circulation lifetimes and tumor selective gene expression. Biochim. Biophys. Acta 1669 (2005) 155-163
2. Chaubal M. Polylactides/glycolides-excipients for injectable drug. Drug Deliv. Technol. 2 (2002) 34-36
3. Gunatillake P.A., and Adhikari R. Biodegradable synthetic polymers for tissue engineering. Eur. Cell Mater. 5 (2003) 1-16
4. Hatakeyama H., Akita H., Kogure K., Oishi M., Nagasaki Y., Kihira Y., Ueno M., Kobayashi H., Kikuchi H., and Harashima H. Development of a novel systemic gene delivery system for cancer therapy with a tumor-specific cleavable PEG-lipid. Gene Ther. 14 (2007) 68-77
5. Ishihara T., Izumo N., Higaki M., Shimada E., Hagi T., Mine L., Ogawa Y., and Mizushima Y. Role of zinc in formulation of PLGA/PLA nanoparticles encapsulating betamethasone phosphate and its release profile. J. Control. Release 105 (2005) 68-76
6. Ishihara T., Takahashi M., Higaki M., Takenaga M., Mizushima T., and Mizushima Y. Prolonging the in vivo residence time of prostaglandin E1 with biodegradable nanoparticles. Pharm. Res. 25 (2008) 1686-1695
7. Ishihara T., Takahashi M., Higaki M., and Mizushima Y. Efficient encapsulation of a water-soluble corticosteroid in biodegradable nanoparticles. Int. J. Pharm. 365 (2009) 200-205
8. Ishihara T., Kubota T., Choi T., Takahashi M., Ayano E., Kanazawa H., and Higaki M. Polymeric nanoparticles encapsulating betamethasone phosphate with different release profiles and stealthiness. Int. J. Pharm. 375 (2009) 148-154
9. Ishihara T., Kubota T., Choi T., and Higaki M. Treatment of experimental arthritis with stealth-type polymeric nanoparticles encapsulating betamethasone phosphate. J. Pharm. Exp. Ther. 329 (2009) 412-417
10. Kim S.Y., Han Y.K., Kim Y.K., and Hong S.I. Multifunctional initiation of lactide polymerization by stannous octoate/pentaerythritol. Makromol. Chem. 193 (1992) 1623-1631
11. Maeda H., Wu J., Sawa T., Matsumura Y., and Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J. Control. Release 65 (2000) 271-284
12. Mishra S., Webster P., and Davis M.E. PEGylation significantly affects cellular uptake and intracellular trafficking of non-viral gene delivery particles. Eur. J. Cell Biol. 83 (2004) 97-111
13. Moghimi S.M., Hunter A.C., and Murray J.C. Long-circulating and target-specific nanoparticles: theory to practice. Pharm. Res. 53 (2001) 283-318
14. Peer D., Karp J.M., Hong S., Farokhzad O.C., Margalit R., and Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat. Nanotechnol. 2 (2007) 751-760
15. Plard J.P., and Bazile D. Comparison of the safety profiles of PLA50 and Me.PEG-PLA50 nanoparticles after single dose intravenous administration to rat. Colloids Surf. B: Biointerfaces 16 (1999) 173-183
16. Riley T., Stolnik S., Heald C.R., Xiong C.D., Garnett M.C., Illum L., and Davis S.S. Physicochemical evaluation of nanoparticles assembled from poly(lactic acid)-poly(ethylene glycol) (PLA-PEG) block copolymers as drug delivery vehicles. Langmuir 17 (2001) 3168-3174
17. Romberg B., Hennink W.E., and Storm G. Sheddable coatings for long-circulating nanoparticles. Pharm. Res. 25 (2008) 55-71
18. Shive M.S., and Anderson J.M. Biodegradation and biocompatibility of PLA and PLGA microspheres. Adv. Drug Deliv. Rev. 28 (1997) 5-24
19. Wendt R.H., and Fassel V.A. Induction-coupled plasma spectrometric excitation source. Anal. Chem. 37 (1965) 920-922
20. Wischke C., and Schwendeman S.P. Principles of encapsulating hydrophobic drugs in PLA/PLGA microparticles. Int. J. Pharm. 364 (2008) 298-327
21. Yih T.C., and Al-Fandi M. Engineered nanoparticles as precise drug delivery systems. J. Cell. Biochem. 97 (2006) 1184-1190